Downtown New Brunswick has officially cemented its status as the heartbeat of New Jersey’s life sciences sector. On October 15, the New Brunswick Development Corp. (DEVCO) announced that Aquestive Therapeutics Inc., a specialty pharmaceutical leader, has relocated its critical research and development operations to H1, the flagship tower of the Health + Life Science Exchange (HELIX).
Occupying a 5,000-square-foot, turnkey lab suite on the building’s 10th floor, Aquestive’s arrival is more than just a lease agreement; it represents a strategic alignment between a cutting-edge innovator and a multi-billion-dollar project designed to foster the next generation of medical breakthroughs. As the HELIX continues its rapid development, it is transforming 20 French St. into a high-octane environment where, for the first time, the state’s research giants, burgeoning startups, and academic powerhouses are physically bridged by architecture and infrastructure.
The Main Facts: A Hub for Innovation
The HELIX is the centerpiece of a transformative vision for Middlesex County. H1, the first of three planned towers, has become a focal point for the “New Jersey Innovation Hub,” which saw its official launch this past summer. The project is designed to eliminate the “friction” that often plagues the life sciences industry—the time-consuming, capital-intensive process of sourcing and building lab space.
Aquestive Therapeutics, headquartered in Warren, New Jersey, is a company defined by its proprietary PharmFilm® technology. By utilizing oral film formations—reminiscent of common breath strips—Aquestive enables the rapid absorption of active drug ingredients without the need for water or liquid. This delivery method has massive implications for patient compliance and emergency medicine. By moving into the HELIX, the company gains immediate access to a "plug-and-play" environment, allowing its scientists to bypass months of construction and move directly into active research.
A Chronology of Progress
The momentum behind the HELIX has been building for years, but the last several weeks have marked a period of rapid acceleration:
- Summer 2026: The New Jersey Innovation Hub officially launches at the HELIX, opening the doors of H1 to a mix of established corporations and high-potential startups.
- Early October 2026: The Johnson & Johnson Exchange, located on the ninth floor of H1 and powered by Portal Innovations, celebrates its grand opening. The event draws a "who’s who" of New Jersey’s life sciences landscape, including J&J CEO Joaquin Duato and Rutgers President William Tate IV.
- October 6, 2026: A formal ribbon-cutting ceremony takes place, underscoring the collaborative intent of the space, which features a central, symbolic staircase connecting the J&J Exchange to the “step-up” labs on the 10th floor.
- October 15, 2026: DEVCO officially announces Aquestive Therapeutics as the latest tenant. On the same day, the company receives a critical update from the U.S. Food & Drug Administration (FDA) regarding its New Drug Application for Anaphylm, with a Prescription Drug Fee Act (PDUFA) goal date set for March 15, 2027.
Supporting Data: Why Aquestive Matters
Aquestive is not merely a tenant; it is an R&D powerhouse. The company manages the entire lifecycle of its products, from discovery to commercialization, and serves as an exclusive manufacturer for products marketed across six continents.
Their pipeline includes the AdrenaVerse platform, a library of more than 20 epinephrine prodrugs, and the highly anticipated Anaphylm sublingual film. If the FDA approves Anaphylm in March 2027, it will mark a historic shift in the treatment of Type 1 allergic reactions. Currently, patients suffering from anaphylaxis must rely on injectable epinephrine. Aquestive’s oral film would provide the first and only non-invasive rescue medication for severe allergic reactions.
The decision to house this work at the HELIX is supported by the facility’s unique architecture. As Jason Benson, senior managing director at JLL—the firm that brokered the deal—points out, the "turnkey" nature of the 10th-floor labs is a massive differentiator. "Aquestive needed lab space that was ready on day one," Benson noted. "This lets their scientists get to work immediately, alleviating the construction risk associated with traditional lab development."
Official Responses and Strategic Vision
The move has been lauded by both public and private sector leaders as a validation of the HELIX concept. DEVCO President Christopher Paladino emphasized that the project was specifically engineered to support companies like Aquestive.
"Our decision to establish our R&D operations at The Helix reflects both where Aquestive is today and where we are going," said Daniel Barber, president and CEO of Aquestive. Barber highlighted the specific benefits of the location: "The combination of ready-to-use lab space, access to talent, and a growing life sciences community gives our team an environment where we can collaborate and continue developing innovative medicines for patients."
The synergy is further supported by the geographic and physical layout of the building. The proximity to the New Brunswick train station, coupled with the neighboring Rutgers University medical facilities, creates a "rare combination of efficiency and connectivity," according to Benson.
The Implications: A New Era for New Jersey
The implications of this move extend far beyond the 5,000 square feet occupied by Aquestive. The HELIX is fundamentally changing how the regional life sciences industry operates. By physically connecting the "startup" labs (where smaller companies begin) with the "enterprise" suites (where companies like Aquestive reside), the project facilitates a "graduation" path for innovators.
The presence of companies like Aquestive—which are actively navigating the FDA approval process—brings a high level of professional prestige and activity to the site. This creates a feedback loop: as more established, publicly traded companies join the HELIX, the ecosystem becomes more attractive to top-tier talent, venture capital firms, and academic researchers.
Furthermore, the scale of the HELIX project—which will eventually include three towers—suggests that this is only the beginning. H2 is already slated to serve as the new headquarters for Nokia Bell Labs, bringing a different, but equally powerful, type of innovation into the mix. H3, a 43-story tower, will add a residential and lifestyle component, ensuring that the "live-work-play" ecosystem remains vibrant around the clock.
In his remarks at the recent ribbon-cutting, Paladino captured the essence of the project’s ambition: "We have extraordinary universities, we have world-class healthcare systems, we have the greatest concentration of pharmaceutical and life science companies everywhere. What we needed was a place to bring them together."
With Aquestive Therapeutics now calling the 10th floor of H1 home, the HELIX has proven it is that place. By blending high-speed, ready-to-use infrastructure with a dense network of cross-industry collaborators, New Brunswick is setting a new standard for how modern medicine is discovered, developed, and delivered. The success of this integration will likely serve as a blueprint for innovation districts across the United States in the coming decade, proving that in the world of high-stakes R&D, physical environment is not just an asset—it is a competitive advantage.
